Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of the Safety and Efficacy of Upadacitinib in Treating Crohn’s Disease Among East Asian Patients: A Post Hoc Evaluation of Phase 3 Randomized Trials

  • By

  • Minhu Chen

  • Xiang Gao

  • Kenji Watanabe

  • Toshimitsu Fujii

  • Jae Hee Cheon

  • Shu-Chen Wei

  • Yuh-Ying Yeh

  • Yasuko Ishikawa

  • Patrick M. Hecht

  • Andrew Garrison

  • Irina Fish

  • Fernando Aponte

  • Silvio Danese

  • Hiroshi Nakase

  • August 30, 2026

Share

  • 1

    Crohn's disease incidence in East Asia has reached an estimated 3.2 per 100,000 person-years, with a prevalence of 31.9 per 100,000 people.

  • 2

    Distinct genetic and environmental risk factors for Crohn's disease exist in East Asian populations compared to Western populations.

  • 3

    Upadacitinib, an oral Janus kinase inhibitor, was evaluated for its efficacy and safety in East Asian patients with moderately to severely active Crohn's disease.

  • 4

    The study included patients from Japan, China, Korea, Taiwan, Hong Kong, Singapore, and Malaysia aged 18-75 with active Crohn's disease.

  • 5

    Safety assessments monitored treatment-emergent adverse events during the clinical trials of upadacitinib for Crohn's disease.

Original Source(s)

Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies

  • by Minhu Chen, Xiang Gao, Kenji Watanabe, Toshimitsu Fujii, Jae Hee Cheon, Shu-Chen Wei, Yuh-Ying Yeh, Yasuko Ishikawa, Patrick M. Hecht, Andrew Garrison, Irina Fish, Fernando Aponte, Silvio Danese, Hiroshi Nakase

  • August 30, 2026

Related Content

Editorial: Metabolite-induced metabolic reprogramming in the immune system

Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece

TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammation